Day One Biopharmaceuticals, Inc.
DAWNNASDAQHealthcare
$21.53
+$0.00(+0.00%)
Market Cap$2.2B
P/E Ratio—
52W High$21.53
52W Low$5.635
Day One Biopharmaceuticals, Inc. (DAWN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DAWN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.35
Est. -$0.31 · -12.9%
Revenue
—
Est. $0.05B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS
DAWN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -$0.31 | -$0.35 | -12.9% | — | $0.05B | — |
| ▼ Q1 FY2026 | Feb 24, 2026 | -$0.17 | -$0.20 | -17.6% | $0.05B | $0.05B | +7.8% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.28 | -$0.19 | +31.8% | $0.04B | $0.04B | +4.2% |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.35 | -$0.29 | +17.1% | $0.03B | $0.04B | -14.4% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.46 | -$0.35 | +23.9% | $0.03B | $0.04B | -15.8% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -$0.35 | -$0.69 | -97.1% | $0.03B | $0.03B | -3.5% |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.41 | $0.38 | +192.7% | $0.09B | $0.03B | +229.2% |
| ▲ Q3 FY2024 | Jul 30, 2024 | -$0.67 | -$0.05 | +92.5% | $0.01B | $0.00B | +698.3% |
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.35
EPS Est.
-$0.31
EPS Surpr.
-12.9%
Revenue
—
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
-$0.20
EPS Est.
-$0.17
EPS Surpr.
-17.6%
Revenue
$0.05B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.28
EPS Surpr.
+31.8%
Revenue
$0.04B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.35
EPS Surpr.
+17.1%
Revenue
$0.03B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.35
EPS Est.
-$0.46
EPS Surpr.
+23.9%
Revenue
$0.03B
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
-$0.69
EPS Est.
-$0.35
EPS Surpr.
-97.1%
Revenue
$0.03B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$0.38
EPS Est.
-$0.41
EPS Surpr.
+192.7%
Revenue
$0.09B
Q3 FY2024
Jul 30, 2024Beat
EPS Actual
-$0.05
EPS Est.
-$0.67
EPS Surpr.
+92.5%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.16 | $-0.14 | $-0.13 | 1 |
| Q3 FY2027 | $-0.16 | $-0.14 | $-0.13 | 1 |
| Q2 FY2027 | $-0.19 | $-0.17 | $-0.15 | 1 |
| Q1 FY2027 | $-0.20 | $-0.18 | $-0.16 | 1 |
| Q4 FY2026 | $-0.18 | $-0.16 | $-0.14 | 1 |
| Q3 FY2026 | $-0.19 | $-0.16 | $-0.15 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 4 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 4 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -12.9% | $21.53 | — | — |
| ▼ Q1 FY2026 | Feb 24, 2026 | -17.6% | $11.70 | $12.02 | +2.74% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +31.8% | $7.31 | $7.30 | -0.14% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +17.1% | $6.74 | $6.88 | +2.08% |
| ▲ Q2 FY2025 | May 6, 2025 | +23.9% | $7.48 | $6.99 | -6.55% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -97.1% | $12.18 | $11.82 | -2.96% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +192.7% | $14.35 | $14.47 | +0.84% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +92.5% | $15.36 | $15.19 | -1.11% |
Q2 FY2026—
Report Date
May 5, 2026
EPS Beat/Miss
-12.9%
Price Before
$21.53
Price After
—
Q1 FY2026+2.74%
Report Date
Feb 24, 2026
EPS Beat/Miss
-17.6%
Price Before
$11.70
Price After
$12.02
Q4 FY2025-0.14%
Report Date
Nov 4, 2025
EPS Beat/Miss
+31.8%
Price Before
$7.31
Price After
$7.30
Q3 FY2025+2.08%
Report Date
Aug 5, 2025
EPS Beat/Miss
+17.1%
Price Before
$6.74
Price After
$6.88
Q2 FY2025-6.55%
Report Date
May 6, 2025
EPS Beat/Miss
+23.9%
Price Before
$7.48
Price After
$6.99
Q1 FY2025-2.96%
Report Date
Feb 25, 2025
EPS Beat/Miss
-97.1%
Price Before
$12.18
Price After
$11.82
Q4 FY2024+0.84%
Report Date
Oct 30, 2024
EPS Beat/Miss
+192.7%
Price Before
$14.35
Price After
$14.47
Q3 FY2024-1.11%
Report Date
Jul 30, 2024
EPS Beat/Miss
+92.5%
Price Before
$15.36
Price After
$15.19
Avg Beat Reaction-0.98%
Avg Miss Reaction-0.11%
Beat Rate5 / 8 quarters
Largest Move-6.55% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DAWN ends December
Day One Biopharmaceuticals, Inc. (DAWN) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.35 — missing the analyst consensus of $-0.31 by -12.9%. The next DAWN earnings date is expected around September 1, 2026.
Each quarter, investors track DAWN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DAWN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DAWN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DAWN earnings · 5 questionsDay One Biopharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. DAWN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DAWN historically reports after market close (AMC).
DAWN earnings datewhen is DAWN earningsDAWN next earnings datewhen does DAWN report earningsDAWN earnings calendar
▸ Source: FMP · Day One Biopharmaceuticals, Inc. SEC filings · US GAAP · Day One Biopharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026